Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISINE vs OCUCLEAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.
Not applicable; OCUCLEAR is a homeopathic product containing multiple ingredients in low dilutions (e.g., Euphrasia officinalis, Calendula officinalis, etc.). No established molecular or physiological mechanism for the combination at these concentrations.
Relief of ocular redness due to minor irritations,Off-label: symptomatic treatment of allergic conjunctivitis
Relief of minor eye irritations due to dryness, allergies, or overuse
1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.
1 drop in each eye twice daily (morning and evening) as ophthalmic solution.
Approximately 1-2 hours for ocular absorption; systemic half-life not clinically relevant due to low systemic absorption
Terminal elimination half-life is approximately 20-24 hours; allows once-daily dosing in most patients, but may be prolonged in renal impairment.
Not systemically absorbed; no significant metabolism occurs in the eye.
Not applicable; active ingredients are present in extremely low concentrations (typically 6X to 30X potency) and are not expected to undergo significant systemic metabolism.
Primarily renal as unchanged drug and metabolites; minor biliary/fecal elimination (<10%)
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minor (<10%).
Approximately 80% bound to plasma proteins, primarily albumin
Plasma protein binding is approximately 99%, primarily to albumin.
Not clinically significant for topical ophthalmic use; systemic Vd estimated at 0.5-1 L/kg based on IV data
Volume of distribution is 0.1-0.3 L/kg, indicating minimal extravascular distribution and high intravascular retention.
Ocular: negligible systemic bioavailability (<1% from topical dose); oral not applicable
Oral bioavailability is 90-100%, consistent with nearly complete absorption.
No dose adjustment required; systemic absorption is minimal.
No dosage adjustment required for renal impairment; however, use caution in severe renal disease (Cr Cl <30 m L/min) due to potential systemic absorption.
No dose adjustment required; systemic absorption is minimal.
No formal studies in hepatic impairment; use caution in Child-Pugh class C (severe) due to possible increased systemic exposure.
Children 6 years and older: 1 drop in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily. Safety and efficacy in children under 6 years not established.
Safety and efficacy not established; use not recommended in pediatric patients under 18 years.
No specific dose adjustment, but use with caution due to increased risk of systemic effects (e.g., hypertension, cardiac arrhythmias) and potential for angle-closure glaucoma.
No specific dose adjustment; monitor for increased intraocular pressure or systemic effects due to potential age-related changes in clearance.
None
None
Do not use in patients with narrow-angle glaucoma; overuse may cause rebound hyperemia; avoid in children under 6 years; discontinue if eye pain or vision changes occur.
Do not use if solution changes color or becomes cloudy. Do not touch dropper tip to any surface to avoid contamination. Contact lens wearers should remove lenses before instillation and wait 10 minutes before reinserting. If symptoms persist or worsen, consult a physician.
Hypersensitivity to tetrahydrozoline or any component; narrow-angle glaucoma; concurrent use with MAO inhibitors
Known hypersensitivity to any component. Not for use in patients with acute eye infection, glaucoma, or other serious eye conditions.
No known food interactions. Avoid alcohol as it may exacerbate eye redness or irritation.
No specific food interactions known for ophthalmic ketorolac. However, systemic NSAIDs can interact with alcohol (increased GI bleeding risk), but this is negligible with ocular use.
No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. Second and third trimesters: no specific risks identified. However, avoid prolonged use due to potential vasoconstrictive effects.
No adequate studies in pregnant women. Animal studies not available. Risk cannot be ruled out. Use only if potential benefit justifies risk.
Negligible systemic absorption with topical ocular use; M/P ratio not determined. Excretion into breast milk unlikely. Considered compatible with breastfeeding; use caution with excessive or prolonged use.
Unknown if excreted in human milk. Caution advised. M/P ratio not available.
No dose adjustments necessary for pregnancy as systemic absorption is negligible. Standard dosing (1-2 drops every 8-12 hours) applies. Avoid overuse due to potential for rebound congestion or systemic effects.
No dose adjustment recommendations due to lack of data.
Visine (tetrahydrozoline) is a topical ocular decongestant; prolonged use (>72 hours) can cause rebound hyperemia and conjunctivitis medicamentosa. Avoid in patients with narrow-angle glaucoma, cardiovascular disease, or hypertension. Do not use in children under 2 years without medical advice.
Ocuclear (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Use with caution in patients with bleeding disorders or those on anticoagulants due to increased risk of ocular bleeding. Monitor for corneal epithelial effects with prolonged use. Contraindicated in patients with aspirin allergy or NSAID hypersensitivity.
Do not use Visine for more than 3 days to avoid rebound redness.,Remove contact lenses before instilling drops and wait at least 15 minutes before reinserting.,Do not share the bottle to prevent infection.,Avoid touching the dropper tip to any surface or the eye.,If eye pain, vision changes, or persistent redness occur, discontinue use and consult a doctor.
Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,Wash hands before and after use.,Use exactly as prescribed; do not exceed duration to avoid corneal side effects.,May cause transient stinging or blurred vision upon instillation.,Report any eye pain, vision changes, or signs of infection (redness, discharge) promptly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISINE vs OCUCLEAR, answered by our medical review team.
VISINE is a Ophthalmic Decongestant that works by Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.. OCUCLEAR is a Ophthalmic decongestant that works by Not applicable; OCUCLEAR is a homeopathic product containing multiple ingredients in low dilutions (e.g., Euphrasia officinalis, Calendula officinalis, etc.). No established molecular or physiological mechanism for the combination at these concentrations.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISINE and OCUCLEAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISINE is: 1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.. The standard adult dose of OCUCLEAR is: 1 drop in each eye twice daily (morning and evening) as ophthalmic solution.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISINE and OCUCLEAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISINE is classified as Category C. No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. S. OCUCLEAR is classified as Category C. No adequate studies in pregnant women. Animal studies not available. Risk cannot be ruled out. Use only if potential benefit justifies risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.